FDA Extends Review Clock for ELREXFIO Biological Product
Published Date: 5/12/2025
Notice
Summary
The FDA has officially set the review period for ELREXFIO, a new human biological product. This means the company behind ELREXFIO can apply to extend their patent, giving them more time to protect their invention. This helps the company keep their exclusive rights longer, potentially affecting when generic versions can enter the market.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Patent-extension eligibility for ELREXFIO
The FDA has determined the regulatory review period for ELREXFIO. The company that makes ELREXFIO can apply to the U.S. Patent and Trademark Office to extend a patent that claims this human biological product, giving the company more time to protect its invention.
Timing of generics may be affected
Because the company can seek to extend its patent and keep exclusive rights longer, the timing of when generic versions of ELREXFIO can enter the market may be affected. That could change when lower-cost generic alternatives become available.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in